Teduglutide vs Glepaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Gattex, Revestive
Teduglutide is a 33-amino-acid GLP-2 analog approved for short bowel syndrome (SBS) in people who depend on IV nutrition or fluids. GLP-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. The FDA approved it as Gattex in December 2012 (children 1 year and older were added in 2019), and in Europe it is sold as Revestive. It works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement.
Also: ZP1848, Zeydovio
Glepaglutide is Zealand Pharma's long-acting GLP-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. Its path has been bumpy. The FDA rejected it in December 2024 because the single phase 3 trial only worked at the twice-weekly dose, but Europe went the other way: in September 2026 the EMA's CHMP recommended approval under the name Zeydovio. As of late October 2026 the final European Commission decision is still pending, and the US needs another trial.
Key Comparison Insights
- Teduglutide is FDA approved, while Glepaglutide remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Teduglutide has stronger research evidence (FDA Approved) compared to Glepaglutide (Human Trials).
Detailed Comparison
| Attribute | Teduglutide | Glepaglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Teduglutide differs from natural GLP-2 by one amino acid (glycine swapped in at position 2), which shields it from DPP-4 breakdown and stretches its half-life from minutes to roughly 2 hours in healthy people (1.3 hours in SBS). It binds GLP-2 receptors on cells in the intestinal wall, which release local growth factors that increase villus height and crypt depth, improve blood flow to the gut, and slow gastric emptying and secretions. Net result: more absorptive surface and more time to absorb. The same growth signal is the reason for its main safety concern, because it can also speed the growth of polyps or existing tumors in the gut, so the label requires colonoscopy before and during treatment. | Glepaglutide activates the GLP-2 receptor in the intestine, the same target as teduglutide, which makes the gut lining grow and absorb more fluid and nutrients. What is different is the delivery. After a subcutaneous injection it forms a depot and is slowly released, mostly as two active metabolites rather than the parent molecule. In a healthy-volunteer study the effective half-life was roughly 88 to 124 hours, long enough to make weekly or twice-weekly dosing plausible. The flip side is the same as the rest of the GLP-2 class: anything that makes gut tissue grow raises questions about polyps and tumors over the long run. |
| Common Dosing | 0.05 mg/kg once daily (labeled dose) Once daily | 10 mg twice weekly (trial dose) Twice weekly |
| Administration | Subcutaneous injection, rotating between abdominal quadrants, thighs, or arms | Subcutaneous injection (prefilled pen in the EU filing) |
| Typical Duration | Long-term, with assessment of benefit and ongoing monitoring; IV support is weaned as absorption improves | 24 weeks in EASE-1, with longer-term extension studies |
| Best Time to Take | Same time each day, any time of day | Same days each week (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | In the pivotal adult trial (Study 1, NCT00798967), 86 adults with SBS were randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks. 63% on teduglutide versus 30% on placebo were responders (at least a 20% cut in weekly IV support at weeks 20 and 24), and weekly IV volume fell 4.4 L versus 2.3 L. In the 2-year open-label extension, 93% of the 30 patients who completed 30 months reached at least a 20% reduction, and a minority came off IV support entirely. An earlier trial (Study 3) used a different primary endpoint that missed at the higher dose, though responder rates at 0.05 mg/kg were 46% versus 6%. A 24-week pediatric study of 59 children aged 1 to 17 led to the 2019 approval: 69% on 0.05 mg/kg cut IV support by at least 20%, and 3 of 26 weaned off. Honest caveats: it is a lifelong therapy for most, benefits fade if stopped, and colon-in-continuity patients often respond less dramatically than those with a stoma. Longer-acting GLP-2 drugs (glepaglutide, apraglutide) are trying to replace the daily shot. | The main evidence is EASE-1, published in Gastroenterology in April 2025 (Jeppesen and colleagues). It randomized 106 adults with SBS and intestinal failure to glepaglutide 10 mg twice weekly, 10 mg once weekly, or placebo for 24 weeks. Twice weekly cut weekly parenteral support by 5.13 L versus 2.85 L on placebo (p=0.0039), and 65.7% were responders versus 38.9% on placebo. Once weekly (3.13 L) did not reach significance. A handful of patients came off IV support completely, none on placebo. On 19 December 2024 the FDA issued a complete response letter saying there was not enough evidence at the to-be-marketed dose and asked for another trial; Zealand is running EASE-5 to support a US resubmission. Zealand filed in Europe in June 2025 and the CHMP gave a positive opinion on 17 September 2026 for adults with SBS (10 mg prefilled pen). Common side effects listed by the EMA are injection site reactions, abdominal pain, nausea, and vomiting. Bottom line: real phase 3 data, but from a single trial with one of two doses positive, which is exactly why the two regulators disagreed. |
Frequently Asked Questions: Teduglutide vs Glepaglutide
What is the difference between Teduglutide and Glepaglutide?
Teduglutide is a healing peptide that teduglutide is a 33-amino-acid glp-2 analog approved for short bowel syndrome (sbs) in people who depend on iv nutrition or fluids. glp-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. the fda approved it as gattex in december 2012 (children 1 year and older were added in 2019), and in europe it is sold as revestive. it works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement. Glepaglutide is a healing peptide that glepaglutide is zealand pharma's long-acting glp-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. its path has been bumpy. the fda rejected it in december 2024 because the single phase 3 trial only worked at the twice-weekly dose, but europe went the other way: in september 2026 the ema's chmp recommended approval under the name zeydovio. as of late october 2026 the final european commission decision is still pending, and the us needs another trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Teduglutide or Glepaglutide?
Neither is universally "better" - the choice depends on your specific goals. Teduglutide is typically used for healing purposes, while Glepaglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Teduglutide and Glepaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Teduglutide and Glepaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.